Connection

Patrick O'Neil to Male

Back to Details
This is a "connection" page, showing publications Patrick O'Neil has written about Male.
Patrick O'Neil
Connection Strength
0.632
Male
  1. Changes in weight control behaviors and hedonic hunger in a commercial weight management program adapted for individuals with type 2 diabetes. Int J Obes (Lond). 2020 05; 44(5):990-998.
    View in: PubMed
    Score: 0.038
  2. Evaluation of a Lifestyle Change Worksite Weight Management Program Across Multiple Employers and Sites. J Occup Environ Med. 2018 12; 60(12):1112-1115.
    View in: PubMed
    Score: 0.035
  3. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018 08 25; 392(10148):637-649.
    View in: PubMed
    Score: 0.034
  4. Characteristics of Weight Loss Trajectories in a Comprehensive Lifestyle Intervention. Obesity (Silver Spring). 2017 12; 25(12):2062-2067.
    View in: PubMed
    Score: 0.032
  5. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017 11; 19(11):1529-1536.
    View in: PubMed
    Score: 0.032
  6. Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes: Results of a randomized controlled trial. J Diabetes Complications. 2017 May; 31(5):891-897.
    View in: PubMed
    Score: 0.031
  7. Randomized controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes. Obesity (Silver Spring). 2016 11; 24(11):2269-2277.
    View in: PubMed
    Score: 0.030
  8. Effects on cardiovascular risk factors of weight losses limited to 5-10. Transl Behav Med. 2016 09; 6(3):339-46.
    View in: PubMed
    Score: 0.030
  9. EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS. Endocr Pract. 2016 11; 22(11):1277-1287.
    View in: PubMed
    Score: 0.030
  10. Changes in cardiovascular risk factors with participation in a 12-week weight loss trial using a commercial format. Eat Behav. 2014 Jan; 15(1):68-71.
    View in: PubMed
    Score: 0.025
  11. Relations of hedonic hunger and behavioral change to weight loss among adults in a behavioral weight loss program utilizing meal-replacement products. Behav Modif. 2013 Nov; 37(6):790-805.
    View in: PubMed
    Score: 0.024
  12. Changes in weight control behaviors and hedonic hunger during a 12-week commercial weight loss program. Eat Behav. 2012 Dec; 13(4):354-60.
    View in: PubMed
    Score: 0.022
  13. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012 Jul; 20(7):1426-36.
    View in: PubMed
    Score: 0.022
  14. Socially desirable responding by bariatric surgery candidates during psychological assessment. Surg Obes Relat Dis. 2013 Mar-Apr; 9(2):300-5.
    View in: PubMed
    Score: 0.021
  15. Remission of metabolic syndrome following a 15-week low-calorie lifestyle change program for weight loss. Int J Obes (Lond). 2009 Jan; 33(1):144-50.
    View in: PubMed
    Score: 0.017
  16. Utility and validity of the eating behavior inventory in clinical obesity research: a review of the literature. Obes Rev. 2005 Aug; 6(3):209-16.
    View in: PubMed
    Score: 0.014
  17. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict Biol. 2004 Mar; 9(1):59-65.
    View in: PubMed
    Score: 0.013
  18. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res. 2002 Jul; 10(7):633-41.
    View in: PubMed
    Score: 0.011
  19. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 01 11; 327(2):138-150.
    View in: PubMed
    Score: 0.011
  20. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 04 13; 325(14):1403-1413.
    View in: PubMed
    Score: 0.010
  21. The perceived relative worth of reaching and maintaining goal weight. Int J Obes Relat Metab Disord. 2000 Aug; 24(8):1069-76.
    View in: PubMed
    Score: 0.010
  22. Vitamin D Supplementation and Prevention of Type 2 Diabetes. N Engl J Med. 2019 08 08; 381(6):520-530.
    View in: PubMed
    Score: 0.009
  23. Description, utilisation and results from a telehealth primary care weight management intervention for adults with obesity in South Carolina. J Telemed Telecare. 2020 Jan-Feb; 26(1-2):28-35.
    View in: PubMed
    Score: 0.009
  24. Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. Diabetes Care. 2018 08; 41(8):1590-1599.
    View in: PubMed
    Score: 0.008
  25. Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study. Obesity (Silver Spring). 2018 01; 26(1):61-69.
    View in: PubMed
    Score: 0.008
  26. Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers. Obesity (Silver Spring). 2016 11; 24(11):2278-2288.
    View in: PubMed
    Score: 0.008
  27. The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. Int J Obes (Lond). 2016 09; 40(9):1369-75.
    View in: PubMed
    Score: 0.007
  28. Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes. Obesity (Silver Spring). 2014 Oct; 22(10):2137-46.
    View in: PubMed
    Score: 0.006
  29. Executive control circuitry differentiates degree of success in weight loss following gastric-bypass surgery. Obesity (Silver Spring). 2013 Nov; 21(11):2189-2196.
    View in: PubMed
    Score: 0.006
  30. Factors associated with development of excessive fatness in children and adolescents: a review of prospective studies. Obes Rev. 2013 Aug; 14(8):645-58.
    View in: PubMed
    Score: 0.006
  31. The Food Craving Questionnaire-Trait in a bariatric surgery seeking population and ability to predict post-surgery weight loss at six months. Eat Behav. 2012 Dec; 13(4):366-70.
    View in: PubMed
    Score: 0.006
  32. Prefrontal cortex transcranial direct current stimulation (tDCS) temporarily reduces food cravings and increases the self-reported ability to resist food in adults with frequent food craving. Appetite. 2011 Jun; 56(3):741-6.
    View in: PubMed
    Score: 0.005
  33. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011 Jan; 19(1):110-20.
    View in: PubMed
    Score: 0.005
  34. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring). 2009 Jan; 17(1):30-9.
    View in: PubMed
    Score: 0.004
  35. The association between food cravings and consumption of specific foods in a laboratory taste test. Appetite. 2008 Sep; 51(2):324-6.
    View in: PubMed
    Score: 0.004
  36. Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity (Silver Spring). 2007 Apr; 15(4):895-905.
    View in: PubMed
    Score: 0.004
  37. A comparison of mental health hospital admissions in a cohort of heroin users prior to and after rapid opiate detoxification and oral naltrexone maintenance. Am J Drug Alcohol Abuse. 2007; 33(5):655-64.
    View in: PubMed
    Score: 0.004
  38. Vagus nerve stimulation acutely alters food craving in adults with depression. Appetite. 2007 Mar; 48(2):145-53.
    View in: PubMed
    Score: 0.004
  39. Changes in food cravings during low-calorie and very-low-calorie diets. Obesity (Silver Spring). 2006 Jan; 14(1):115-21.
    View in: PubMed
    Score: 0.004
  40. Findings and outcomes of psychological evaluations of gastric bypass applicants. Surg Obes Relat Dis. 2005 Nov-Dec; 1(6):523-7; discussion 528-9.
    View in: PubMed
    Score: 0.004
  41. Smoking status and weight loss in three weight loss programs. Eat Behav. 2006 Jan; 7(1):61-8.
    View in: PubMed
    Score: 0.003
  42. Gender, race, and obesity-related quality of life at extreme levels of obesity. Obes Res. 2004 Jun; 12(6):949-55.
    View in: PubMed
    Score: 0.003
  43. Night eating syndrome: effects of brief relaxation training on stress, mood, hunger, and eating patterns. Int J Obes Relat Metab Disord. 2003 Aug; 27(8):970-8.
    View in: PubMed
    Score: 0.003
  44. A prospective study of holiday weight gain. N Engl J Med. 2000 Mar 23; 342(12):861-7.
    View in: PubMed
    Score: 0.002
  45. Psychosocial aspects of total parenteral nutrition. Psychosomatics. 1980 Feb; 21(2):115-25.
    View in: PubMed
    Score: 0.002
  46. Short-term impact of a church-based approach to lifestyle change on cardiovascular risk in African Americans. Ethn Dis. 2000; 10(1):17-23.
    View in: PubMed
    Score: 0.002
  47. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr. 1999 Jun; 69(6):1108-16.
    View in: PubMed
    Score: 0.002
  48. Cognitive appraisals of dietary transgressions by obese women: associations with self-reported eating behavior, depression, and actual weight loss. Int J Obes Relat Metab Disord. 1999 Mar; 23(3):231-7.
    View in: PubMed
    Score: 0.002
  49. Effects of sex of subject and spouse involvement on weight loss in a behavioral treatment program: a retrospective investigation. Addict Behav. 1979; 4(2):167-77.
    View in: PubMed
    Score: 0.002
  50. Prevalence of binge eating disorder in obese adults seeking weight loss treatment. Eat Weight Disord. 1997 Sep; 2(3):117-24.
    View in: PubMed
    Score: 0.002
  51. Neurocognitive deficits in morbidly obese children with obstructive sleep apnea. J Pediatr. 1995 Nov; 127(5):741-4.
    View in: PubMed
    Score: 0.002
  52. Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull. 1993; 29(2):183-8.
    View in: PubMed
    Score: 0.001
  53. Naltrexone and dysphoria: a double-blind placebo controlled trial. Biol Psychiatry. 1987 Jun; 22(6):710-6.
    View in: PubMed
    Score: 0.001
  54. A controlled trial of naltrexone in obese humans. Int J Obes. 1985; 9(5):347-53.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.